Biocept Looking to Redefine CTC Dx Market, Plans Product Launches | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – In the midst of a $5 million financing round, microfluidics company Biocept is looking to launch its first diagnostic test, as it embarks on "redefining what a circulating tumor cell is."

Thirteen years after its founding, and following changes in its technology focus and other adaptations, the company plans to soon launch its first diagnostic test, directed at breast cancer, Biocept President and CEO Stephen Coutts told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.